COVID-19  December 23, 2021

First test patient gets dosed in Statera COVID drug test

FORT COLLINS — Statera Biopharma Inc. (Nasdaq: STAB), a pharmaceutical company formed this year from the merger of Cleveland BioLabs Inc. and Cytocom Inc., has provided its first test patient with a dose of its COVID-19 treatment drug candidate STAT-205.

The drug, in preclinical trials, has shown the potential to block the replication of coronaviruses in human lung cells.

Statera’s randomized, single-blind, placebo-controlled study will enroll 24 adult patients, with preliminary results expected to be reported next year. 

SPONSORED CONTENT

Solar Operations and Maintenance for Commercial Properties

One key qualification to consider when selecting a solar partner to install your system is whether they have an Operations and Maintenance (O&M) or service department. Since solar is a long-term asset with an expected lifecycle of 30 plus years, ongoing O&M should be considered up front. A trusted O&M partner will maximize your system’s energy output and therefor the return on your investment.

“We look forward to working with the researchers to explore the potential of STAT-205 as an oral cost-effective therapeutic option for patients with COVID-19,” Statera CEO Michael Handley said in a prepared statement. 

The company said in August that it’s evaluating or developing 21 drug candidates.  

By the end of the quarter, it completed Phase 2 work on a drug for pediatric Crohn’s disease and is setting up Phase 3, to begin in early 2022.

© 2021 BizWest Media LLC

FORT COLLINS — Statera Biopharma Inc. (Nasdaq: STAB), a pharmaceutical company formed this year from the merger of Cleveland BioLabs Inc. and Cytocom Inc., has provided its first test patient with a dose of its COVID-19 treatment drug candidate STAT-205.

The drug, in preclinical trials, has shown the potential to block the replication of coronaviruses in human lung cells.

Statera’s randomized, single-blind, placebo-controlled study will enroll 24 adult patients, with preliminary results expected to be reported next year. 

“We look forward to working with the researchers to explore the potential of STAT-205 as an oral cost-effective therapeutic option for patients with COVID-19,”…

Sign up for BizWest Daily Alerts